Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation
NCT05379114 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136
Last updated 2022-06-01
Summary
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.
The test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice infestation easy, and effective in few minutes.
The objectives of this clinical study are to assess the efficacy and the safety of a new Medical Device for lice infestation treatment compared to a comparator device, already in market.
Conditions
- Head Lice
Interventions
- OTHER
-
INVESTIGATIONAL DEVICE
new medical device for the treatment of head lice infestation: Paranix ®
- OTHER
-
Comparator device
well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
Sponsors & Collaborators
-
Perrigo CSCI
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-05-18
- Primary Completion
- 2022-07-31
- Completion
- 2022-09-30
Countries
- Mauritius
Study Locations
More Related Trials
-
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
NCT00433914 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
NCT00847145 ·Status: COMPLETED ·Phase: PHASE3
-
MenPF-1 - A New Vaccine Against Meningococcal Disease
NCT01640652 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02679079 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
NCT01274897 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
NCT00310674 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects
NCT01519713 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
NCT01367158 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
NCT00297817 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
NCT03205371 ·Status: COMPLETED ·Phase: PHASE3
-
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
NCT02526394 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
NCT00808028 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
NCT03632720 ·Status: COMPLETED ·Phase: PHASE3
-
Competitive Carriage of Neisseria Spp(Lactamica 2)
NCT02249598 ·Status: COMPLETED ·Phase: NA
-
Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children
NCT01266993 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
NCT02199691 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents
NCT00387725 ·Status: COMPLETED ·Phase: PHASE2
-
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
NCT01352793 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
NCT05836012 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Two Doses of HIL-214 in Children
NCT05281094 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis
NCT01554124 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers
NCT00387569 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)
NCT01565577 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
NCT03137927 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
NCT00471081 ·Status: COMPLETED ·Phase: PHASE2